Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy

Head and Neck

Volumn 28, Issue 2, 2006, Pages 126-134

  Tham, Ivan Weng Keong ^a   Lee, Khai Mun ^b   Yap, Swee Peng ^a   Loong, Susan Li Er ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Chemotherapy; Lymphoma; Nasal; Natural killer; Radiotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER T CELL; NOSE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SINGAPORE; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT FAILURE;

EID: 31444434965     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20314     Document Type: Review

References (30)

1. Kim GE, Lee SW, Chang SK, et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001;61:261-269.
2. Lei KIK, Suen JJS, Hui P, Tong M, Li W, Yau SH. Primary nasal and nasopharyngeal lymphomas: a comparative study of clinical presentation and treatment outcome. Clin Oncol 1999;11:379-387.
3. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993;17:392-399.
4. Fellbaum C, Hansmann ML, Lennert K. Malignant lymphomas of the nasal cavity and paranasal sinuses. Virchows Arch A Pathol Anat Histopathol 1989;414:399-405.
5. Abbondanzo SL, Wenig BM. Non-Hodgkin's lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995;75:1281-1291.
6. + NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997;97:821-829.
7. Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999;111:S46-S55.
8. Harris NL, Jaffe ES, Diebold J, et al. World Health Organisation classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
9. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54:182-190.
10. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996;87:1207-1210.
11. Cheung MMC, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70-77.
12. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features and prognosis. Cancer 1998;83:806-812.
13. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12:349-352.
14. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-670.
15. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54-63.
16. Itami J, Itami M, Mikata A, et al. Non-Hodgkin's lymphoma confined to the nasal cavity: its relationship to the polymorphic reticulosis and results of radiation therapy. Int J Radiat Oncol Biol Phys 1991;20:797-802.
17. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
18. Carbone PP, Kaplan HS, Mushoff L, et al. Report of the Committee on Hodgkin's Disease Staging. Cancer Res 1971;31:1860-1861.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001;15:1123-1126.
21. Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998;83:449-456.
22. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004;15:618-625.
23. Shikama N, Izuno I, Oguchi M, et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997;204:467-470.
24. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
25. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-2356.
26. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176.
27. Kim GE, Yang WI, Lee SW, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004;45:1857-1864.
28. O'Doherty MJ, Macdonald EA, Barrington SF, Mikhaeel NG, Schey S. Positron emission tomography in the management of lymphomas. Clin Oncol 2002;14:415-426.
29. Weihrauch MR, Dietlein M, Schicha H, Diehl V, Tesch H. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003;44:15-22.
30. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.